Companies developing antibiotics to get financial and technical support from more than 20 firms contributing to new AMR Action Fund. Initiative is also pushing for reimbursement reform and other policies to support commercial marketing.

Companies developing antibiotics to get financial and technical support from more than 20 firms contributing to new AMR Action Fund. Initiative is also pushing for reimbursement reform and other policies to support commercial marketing.

A number of companies with marketing applications at the later stages of the EU review process are seeking extra time to address remaining concerns the European Medicines Agency’s drug evaluation committee, the CHMP, has about their filings.

Evan Loh, CEO of infectious disease drug developer Paratek Pharmaceuticals, explains why eliminating the DISARM ACT, which focused on finding solutions against antimicrobial resistance, from the new coronavirus aid package is a shortsighted move by US congress.